Baxter bids general counsel adieu
This article was originally published in The Gray Sheet
Executive Summary
Marla Persky, 48, assumes acting general counsel title in wake of Thomas Sabatino's decision to resign from firm and become Schering-Plough's general counsel, effective April 15. A 16-year Baxter veteran, Persky had been serving as deputy general counsel and managing the law function for the company's renal business, as well as its litigation, regulatory and intercontinental legal teams. Baxter is seeking a permanent replacement for Sabatino, who recently helped craft AdvaMed's code of ethics. The firm continues to work with headhunter Heidrick & Struggles to fill the CEO spot to be vacated by Harry Kraemer (1"The Gray Sheet" Feb. 4, 2004, p. 11)...
You may also be interested in...
Buck Stops With Kraemer: Baxter CEO Resigns To Restore Investor Confidence
A fresh round of restructuring will save Baxter $200 mil.-$300 mil. a year, shore up core business segments and help pave the way for future growth, the firm says
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.